ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

ClinicalTrials.gov ID: NCT02222545

Public ClinicalTrials.gov record NCT02222545. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 9:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Uncontrolled, Three-Stage, Dose-Escalation Cohort Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Clinical Activity of OMS721 in Adults With Thrombotic Microangiopathies

Study identification

NCT ID
NCT02222545
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Omeros Corporation
Industry
Enrollment
58 participants

Conditions and interventions

Interventions

  • OMS721 Biological

Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 1, 2014
Primary completion
Jan 29, 2020
Completion
Aug 10, 2020
Last update posted
Aug 27, 2024

2014 – 2020

United States locations

U.S. sites
5
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Omeros Investigational Site Duarte California 91010
Omeros Investigational Site Rochester Minnesota 55905
Omeros Investigational Site New York New York 10065
Omeros Investigational Site Durham North Carolina 27710
Omeros Investigational Site Madison Wisconsin 53792

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02222545, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 27, 2024 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02222545 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →